"it's not about color. It's about care. It's about a cure."
.                         
Hepatitis C Multicultural Outreach
A Christian, not-for-profit, non-governmental organization whose mission is to improve the health and spiritual status of people in underserved communities by  building the capacity of faith communities to address life-threatening diseases, especially Hepatitis C and HIV/AID. HEP C-MO's achievements have enabled communities of color to become leaders in preventing the transmission of HCV and HIV/AIDS by providing screening, testing, treatment and counseling services (Christian Health and Wellness Clinic), along with comprehensive educational programs and support to encourage those infected to seek and maintain treatment. The Hepatitis C Multicultural Outreach spearheads a dynamic response to the emerging hepatitis C crisis in the faith community.
MVP(Mission, Vision and Philosophy) - Staff - Board of Directors - Statement of Faith
FAQs
hep c in asian american populations

 

Hepatitis B is highly prevalent among Asians and
 Asian-Americans, but hepatitis C in this population is less
 well characterized. As described in the December 2006
American Journal of Gastroenterology
, researchers
conducted a retrospective survey to assess the demographics, epidemiology,
and natural  history of chronic hepatitis C in Asian-Americans. The study
included 260  Asian-American chronic HCV patients referred to a single tertiary
center in California.

Results

92% percent of the study participants were born in Asia.

51% reported a history of unsafe therapeutic injections.

Unsafe injection was a risk factor only for those with HCV exposure
   outside the United States.

41% reported a history of blood transfusion, which was more frequent
  among those with exposure within the Unites States.

Only 3.8% reported a history of injection drug abuse, which was more
   frequent among those with exposure within the United States.

64.2% of patients had HCV genotype 1, 18.3% had genotype 2, and
  11.3% had genotype 6.

Patients with genotype 1 had a significantly lower sustained virological
 response rate to interferon-based therapy, compared to those with geno-
 types 2 or 6 (32.8%, 77.8%, and 69.2%, respectively).

During a mean follow-up period of 6 years, 26 patients developed
  hepatocellular carcinoma (HCC).

A logistic regression model revealed that the following factors predicted
  development of HCC:

- fibrosis stage 4 (OR 8.87);
- older age at presentation (55 vs 35 years: OR 3.45);
- baseline albumin level (3.0 vs 4.0 mg/dL: OR 3.47).

Conclusion

"Asian-Americans with a history of unsafe therapeutic injections must be screened
for chronic hepatitis C," the authors recommended. "Antiviral treatment should be init-
iated prior to development of cirrhosis. Surveillance for HCC must be routinely perform-
ed in cirrhosis patients."

01/30/07

Reference
J T Cheng, C Hsien, H E Sun, and others. The emerging importance of chronic hepat-
itis C infection in Asian Americans. American Journal of Gastroenterology 101(12):
2737-2743. December 2006.

HIVandHepatitis.com

Last Updated ( Sunday, 02 March 2008 )

Hep c- mo Podcast
Listen to hep C interviews and other health-related PodCasts Podcast
Full Feed
KMBC-TV Does Story on Las Vegas, Nevada Outbreak and Hep C-MO Outreach  Read More
 
Hep c -MO global Watch
Asia and the South Pacific - Southeast Asia has an overall prevalence rate of 2.15 percent. Thailand's rate is 5.6 percent, Vietnam 6.1 percent and Cambodia, 4 percent. India is at 1.8 percent and Nepal is at 0.6 percent. Mongolia has the highest rate in Asia, with a 10.7 percent prevalence, while China has a 4 percent rate and Japan has a 2.3 percent rate. Australia and New Zealand both have just 0.3 percent of the population infected.
 
Know the Risks